AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23970114 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading at 30% of MIP
Number of subjects: 25
Study 23970114 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading at 80% of MIP
Number of subjects: 25
Study 21182457 — intervention group
Group type: EXPERIMENTAL
Intervention: V-5 Immunitor (V5) immunotherapy pill
Number of subjects: 55
Study 21182457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19018197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic mist therapy
Number of subjects: 0
Study 19018197 — intervention group
Group type: COMPARATOR
Intervention: Sham device or alternative treatments
Number of subjects: 0
Study 16763747 — intervention group
Group type: EXPERIMENTAL
Intervention: LKFibre diet (17-30 g/day fiber)
Number of subjects: 18
Study 16763747 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study 16763747 — intervention group
Group type: EXPERIMENTAL
Intervention: LKFibre diet
Number of subjects: 18
Study 14670885 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil (920 mg gamma linolenic acid) - adults received four capsules twice daily, children received two capsules twice daily for 12 weeks.
Number of subjects: 140
Study 14670885 — intervention group
Group type: COMPARATOR
Intervention: Placebo - control group receiving placebo treatment for 12 weeks.
Number of subjects: 140
Study 10999788 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH-(1-34) 400 IU daily
Number of subjects: 23
Study 10999788 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 23
Study 8636808 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy
Number of subjects: 16
Study 1512513 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (800 IU/day)
Number of subjects: 12
Study 1512513 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6381579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyaninoside chloride
Number of subjects: 31
Study 6381579 — intervention group
Group type: EXPERIMENTAL
Intervention: Heleniene
Number of subjects: 31
Study 6381579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 31395034 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice and text messages
Number of subjects: 0
Study 31395034 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive telephone-based counselling
Number of subjects: 0
Study 31395034 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no additional phone-based support)
Number of subjects: 0
Study 30012185 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of monomeric and oligomeric flavanols (MOF) daily for 3 months
Number of subjects: 96
Study 30012185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 26728060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-based renal sympathetic denervation (RSD)
Number of subjects: 71
Study 26728060 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 71
Study 26728060 — intervention group
Group type: EXPERIMENTAL
Intervention: RSD (in patients with exaggerated baseline exercise BP)
Number of subjects: 71
Study 26728060 — intervention group
Group type: COMPARATOR
Intervention: Sham (in patients with exaggerated baseline exercise BP)
Number of subjects: 71
Study 24485734 — intervention group
Group type: EXPERIMENTAL
Intervention: Melaleuca alternifolia dental gel
Number of subjects: 34
Study 24485734 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total (Control)
Number of subjects: 34
Study 22178174 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 578
Study 22178174 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (Ben)
Number of subjects: 578
Study 22178174 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM combined with Benazepril (TCM+Ben)
Number of subjects: 578
Study 20129679 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% viscous lignocaine 4mg/kg body weight topically post-tonsillectomy
Number of subjects: 130
Study 20129679 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac 1mg/kg per-rectal post-induction of anaesthesia
Number of subjects: 130
Study 18049362 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric contact lenses (Biomedics 55, SofLens 66)
Number of subjects: 15
Study 18049362 — intervention group
Group type: COMPARATOR
Intervention: Spherical contact lenses
Number of subjects: 15
Study 18049362 — intervention group
Group type: COMPARATOR
Intervention: Toric contact lenses vs. Spherical contact lenses
Number of subjects: 15
Study 15745726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led disease management program
Number of subjects: 217
Study 15745726 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 217
Study 14619641 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate, 10 mg, daily for 6 months
Number of subjects: 11
Study 14619641 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily for 6 months
Number of subjects: 11
Study 10831522 — intervention group
Group type: EXPERIMENTAL
Intervention: ELCA+PTCA
Number of subjects: 249
Study 10831522 — intervention group
Group type: COMPARATOR
Intervention: RA+PTCA
Number of subjects: 249
Study 8553489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic thermometer (FirstTemp)
Number of subjects: 155
Study 8553489 — intervention group
Group type: COMPARATOR
Intervention: Mercury rectal thermometer
Number of subjects: 155
Study 1760826 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ISMN), orally 20 mg 2-3 times daily
Number of subjects: 40
Study 1760826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7051813 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin therapy
Number of subjects: 41
Study 7051813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin therapy
Number of subjects: 41
Study 7051813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin therapy (for relapses)
Number of subjects: 41
Study 31007033 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Attenuation (NA) combined with 2.5% Surfactant (SF)
Number of subjects: 4
Study 31007033 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoremediation (PH) with Surfactant (SF)
Number of subjects: 4
Study 31007033 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (5% SF)
Number of subjects: 4
Study 30346229 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood abuse
Number of subjects: 548
Study 30346229 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 548
Study 30346229 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood physical abuse
Number of subjects: 548
Study 30346229 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 548
Study 26687731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovariohysterectomy (OHE)
Number of subjects: 60
Study 26687731 — intervention group
Group type: COMPARATOR
Intervention: Non-Ovariohysterectomy (non-OHE)
Number of subjects: 60
Study 24211154 — intervention group
Group type: EXPERIMENTAL
Intervention: Static progressive stretch device plus traditional therapy
Number of subjects: 60
Study 24211154 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy alone
Number of subjects: 60
Study 22245666 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-GBD
Number of subjects: 59
Study 22245666 — intervention group
Group type: COMPARATOR
Intervention: PTGBD
Number of subjects: 59
Study 19493980 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS intervention delivered by teachers over a six-month period
Number of subjects: 26
Study 19493980 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training and manuals provided
Number of subjects: 26
Study 19493980 — intervention group
Group type: EXPERIMENTAL
Intervention: Large class sizes and teacher resistance
Number of subjects: 26
Study 19493980 — intervention group
Group type: EXPERIMENTAL
Intervention: Student enthusiasm for lessons
Number of subjects: 26
Study 19493980 — intervention group
Group type: EXPERIMENTAL
Intervention: General disregard for life orientation among students
Number of subjects: 26
Study 17198120 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRING internship program
Number of subjects: 100
Study 17198120 — intervention group
Group type: COMPARATOR
Intervention: Baseline nurses (non-SPRING)
Number of subjects: 100
Study 15857877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone sleeping position during active sleep (AS)
Number of subjects: 63
Study 15857877 — intervention group
Group type: COMPARATOR
Intervention: Supine sleeping position during active sleep (AS)
Number of subjects: 63
Study 15857877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone sleeping position during quiet sleep (QS)
Number of subjects: 63
Study 15857877 — intervention group
Group type: COMPARATOR
Intervention: Supine sleeping position during quiet sleep (QS)
Number of subjects: 63
Study 12078788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) KIU = 280 mg)
Number of subjects: 29
Study 12078788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 29
Study 9559712 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus immune globulin (RSV-IG)
Number of subjects: 39
Study 7621493 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial varnish (Cervitec) containing 1% chlorhexidine and 1% thymol, applied four times over 3 months.
Number of subjects: 18
Study 7621493 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish control, applied four times over 3 months.
Number of subjects: 18
Study 2636677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein and phosphorus diets
Number of subjects: 96
Study 2636677 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study 31242545 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 11
Study 31242545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 28975307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam + Haloperidol
Number of subjects: 93
Study 28975307 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Haloperidol
Number of subjects: 93
Study 28975307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 25740906 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract supplementation (0.56 g/d epigallocatechin gallate + 0.28-0.45 g/d caffeine)
Number of subjects: 60
Study 25740906 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study 22830987 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of rapid-acting insulin analogs
Number of subjects: 18
Study 22830987 — intervention group
Group type: COMPARATOR
Intervention: Conventional pen administration of rapid-acting insulin analogs
Number of subjects: 18
Study 20680244 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-TKA using quadriceps-sparing approach
Number of subjects: 50
Study 20680244 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA using medial parapatellar approach
Number of subjects: 50
Study 19779487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicorder device
Number of subjects: 122
Study 19779487 — intervention group
Group type: COMPARATOR
Intervention: SphygmoCor device
Number of subjects: 122
Study 19779487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicorder device (adjusted)
Number of subjects: 122
Study 16708505 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training condition
Number of subjects: 15
Study 16708505 — intervention group
Group type: COMPARATOR
Intervention: Standard training condition
Number of subjects: 15
Study 15641602 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 269
Study 15641602 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release diclofenac 75 mg
Number of subjects: 269
Study 15641602 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 269
Study 15641602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 11316647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine aerosol inhalation
Number of subjects: 22
Study 11316647 — intervention group
Group type: COMPARATOR
Intervention: Saline aerosol
Number of subjects: 22
Study 9462247 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sucrose-phosphate based transport medium (2-SP) with PCR
Number of subjects: 481
Study 9462247 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sucrose-phosphate based transport medium (2-SP) with LCR
Number of subjects: 481
Study 9462247 — intervention group
Group type: COMPARATOR
Intervention: Shell vial assay
Number of subjects: 481
Study 8191414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin and oral anticoagulant (AC) treatment
Number of subjects: 90
Study 8191414 — intervention group
Group type: COMPARATOR
Intervention: Non-AC treatment with phenylbutazone for ten days
Number of subjects: 90
Study 3283555 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered immunoglobulin concentrate against enterotoxigenic E. coli
Number of subjects: 20
Study 3283555 — intervention group
Group type: COMPARATOR
Intervention: Control immunoglobulin concentrate (no anti-E. coli activity)
Number of subjects: 20
Study 31154419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential co-enrolment in randomized trials
Number of subjects: 0
Study 31154419 — intervention group
Group type: COMPARATOR
Intervention: Previous trial participation
Number of subjects: 0
Study 31066303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 mg oral norethindrone with continuation of transdermal oestradiol patches (NET)
Number of subjects: 3
Study 31066303 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol withdrawal by patch removal (E2WD)
Number of subjects: 3
Study 28801926 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet dissonance-based intervention (DBI-I)
Number of subjects: 271
Study 28801926 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet cognitive-behavioral intervention (CBI-I)
Number of subjects: 271
Study 28801926 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 271
Study 25322923 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food) once-daily during the open-label extension study
Number of subjects: 201
Study 25322923 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food)
Number of subjects: 201
Study 24115838 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 108
Study 24115838 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost and timolol
Number of subjects: 108
Study 22180732 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures (polyglactin-910)
Number of subjects: 1300
Study 22180732 — intervention group
Group type: COMPARATOR
Intervention: Silk sutures (removed at 7-10 days)
Number of subjects: 1300
Study 19230461 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 12 mg
Number of subjects: 39
Study 19230461 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine 60 mg
Number of subjects: 39
Study 19230461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16877197 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 24
Study 16877197 — intervention group
Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 24
Study 15209481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail- and telephone-based weight loss programs
Number of subjects: 1801
Study 15209481 — intervention group
Group type: COMPARATOR
Intervention: General sample of overweight members
Number of subjects: 1801
Study 11523025 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO, epoetin alfa)
Number of subjects: 0
Study 11523025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9442821 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine
Number of subjects: 60
Study 9442821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8376646 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective-taking training strategies
Number of subjects: 0
Study 8376646 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3527811 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS), 2 to 3 g i.v. three hours apart within 12 hours of chest pain onset
Number of subjects: 1158
Study 3527811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1158
Study 3527811 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 1158
Study 30281694 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical congenital heart disease
Number of subjects: 0
Study 30281694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality from congenital heart disease
Number of subjects: 0
Study 30281694 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rate
Number of subjects: 0
Study 30281694 — intervention group
Group type: EXPERIMENTAL
Intervention: Main cause of death
Number of subjects: 0
Study 27344822 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needling therapy and auricular acupuncture (observation group)
Number of subjects: 110
Study 27344822 — intervention group
Group type: COMPARATOR
Intervention: Warm needling therapy (control group)
Number of subjects: 110
Study 25154844 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA group
Number of subjects: 150
Study 25154844 — intervention group
Group type: COMPARATOR
Intervention: NLBN group
Number of subjects: 150
Study 25154844 — intervention group
Group type: COMPARATOR
Intervention: NLBM group
Number of subjects: 150
Study 22388234 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 22388234 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 20581338 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Limb Training and Assessment (ULTrA) program, 40 min/day, 5 days/week for 8 weeks, using a laptop, webcam, target light board, and hand manipulation/discrimination devices.
Number of subjects: 12
Study 17852547 — intervention group
Group type: EXPERIMENTAL
Intervention: RECESS (n=17): Two additional 30-minute periods of outdoor free play time per day for two days
Number of subjects: 32
Study 17852547 — intervention group
Group type: COMPARATOR
Intervention: CON (n=15): Normal classroom schedule
Number of subjects: 32
Study 15676086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment (core temperature maintained at 33-35 degrees C for 3-5 days)
Number of subjects: 86
Study 15676086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 86
Study 15676086 — intervention group
Group type: COMPARATOR
Intervention: Control (normothermia, no hypothermia treatment)
Number of subjects: 86
Study 12374248 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly
Number of subjects: 450
Study 12374248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 10808701 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol 2 mg and norethisterone acetate 1 mg
Number of subjects: 60
Study 10808701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8714860 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 68
Study 8714860 — intervention group
Group type: COMPARATOR
Intervention: Standard zinc therapy
Number of subjects: 68
Study 1533724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 33
Study 1533724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3904873 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg
Number of subjects: 10
Study 3904873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3904873 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine before BCBR
Number of subjects: 10
Study 3904873 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine after BCBR
Number of subjects: 10
Study 30768919 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring with patient-reported outcomes
Number of subjects: 0
Study 30004957 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian gland squeezer
Number of subjects: 70
Study 30004957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 27749534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg, once per week for 3 months
Number of subjects: 40
Study 27749534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25070995 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 PfSPZ
Number of subjects: 24
Study 25070995 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 PfSPZ
Number of subjects: 24
Study 25070995 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 24
Study 22271539 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent preventive intervention targeting physicians, patients, and families
Number of subjects: 1516
Study 22271539 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1516
Study 22271539 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent preventive intervention
Number of subjects: 1516
Study 19644697 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride
Number of subjects: 146
Study 19644697 — intervention group
Group type: EXPERIMENTAL
Intervention: Valethamate bromide
Number of subjects: 146
Study 19644697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 19022155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 7851